Atrion Corporation Stock Intrinsic Value – ATRION CORPORATION Reports Q4 Earnings of USD 8.3 Million, Up 2.3% Year-Over-Year.
March 28, 2023
Earnings Overview
For the fourth quarter of fiscal year 2022, ATRION CORPORATION ($NASDAQ:ATRI) reported total revenue of USD 8.3 million, an increase of 2.3% from the same period one year prior. Net income for the quarter was USD 42.9 million, a 6.4% year-on-year rise. The earnings results were made public on February 27 2023 for the period ending December 31 2022.
Stock Price
On Monday, ATRION CORPORATION reported Q4 earnings of USD 8.3 million, a 2.3% increase from the same quarter last year. The company’s stock opened at $652.6 and closed at the same price, a 4.4% decrease from the previous day’s closing price of 682.8. This report marked ATRION CORPORATION’s fifth consecutive quarter of positive year-over-year earnings growth, an impressive feat considering the challenging economic conditions of the past year. Despite the stock market’s reaction, ATRION CORPORATION has maintained a strong balance sheet and solid financial performance, with strong cash flow and higher revenues compared to the previous year.
ATRION CORPORATION’s Q4 earnings report also highlighted their commitment to sustainable business practices and environmental awareness, as the company was recognized for its efforts in reducing waste and emissions. To further strengthen their sustainability goals, ATRION CORPORATION plans to invest in renewable energy sources in the near future. ATRION CORPORATION’s Q4 earnings report is a testament to the company’s commitment to financial stability and sound business decisions. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Atrion Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 183.51 | 35.01 | 19.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Atrion Corporation. More…
| Operations | Investing | Financing |
| 28.79 | -15.28 | -41.04 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Atrion Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 264.71 | 25.17 | 136.03 |
Key Ratios Snapshot
Some of the financial key ratios for Atrion Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.8% | -0.7% | 21.6% |
| FCF Margin | ROE | ROA |
| -2.7% | 10.2% | 9.4% |
Analysis – Atrion Corporation Stock Intrinsic Value
At GoodWhale, we have conducted a thorough analysis of ATRION CORPORATION‘s overall wellbeing. After our in-depth study, we are confident in determining a fair value of the ATRION CORPORATION share to be around $751.0, which is calculated using our proprietary Valuation Line. Currently, ATRION CORPORATION stocks are listed at $652.6, representing a 13.1% discount from our determined fair price. This implies that ATRION CORPORATION stocks may be a lucrative investment opportunity at its current price, as it may offer investors more purchasing power than its fair value. More…
Peers
In the medical device industry, Atrion Corp competes against LeMaitre Vascular Inc, AtriCure Inc, and Nova Eye Medical Ltd. All four companies offer products that are used to treat cardiovascular diseases. Atrion has a history of innovation, which has allowed it to become a leader in the industry. The company’s competitors have also been successful in their own right, and each offers a unique product portfolio.
– LeMaitre Vascular Inc ($NASDAQ:LMAT)
LeMaitre Vascular Inc is a medical device company that develops, manufactures, and markets vascular devices for the treatment of peripheral vascular disease. Its products are used by vascular surgeons and interventionalists for arterial and venous vessel reconstruction. The company’s products include stents, balloons, and other devices. It has operations in the United States, Europe, Canada, Australia, and Asia.
– AtriCure Inc ($NASDAQ:ATRC)
AtriCure, Inc. is a leading manufacturer of medical devices that provide surgical ablation solutions for the treatment of atrial fibrillation and other cardiac conditions. The company has a market cap of 2.14B as of 2022 and a Return on Equity of -7.05%. AtriCure’s products are sold in over 50 countries and are backed by a strong clinical evidence base. The company’s mission is to improve the lives of patients by providing minimally invasive solutions that treat cardiac conditions with fewer complications and shorter hospital stays.
– Nova Eye Medical Ltd ($ASX:EYE)
Nova Eye Medical Ltd is a publicly traded company that provides ophthalmic products and services. As of 2022, the company had a market capitalization of 40.84 million and a return on equity of -18.79%. Nova Eye Medical Ltd offers a variety of ophthalmic products and services, including cataract surgery, refractive surgery, ocular implants, and more. The company has a presence in both the United States and Canada.
Summary
ATRION CORPORATION released their fourth quarter earnings results for FY2022 on February 27, 2023, indicating an increase in both revenues and net income. Total revenue was reported at USD 8.3 million, a 2.3% increase from the same period last year, while net income showed a 6.4% increase. Despite the positive results, the stock price dropped the same day, indicating that market sentiment and investor expectations were not met. Nevertheless, investors should take into consideration the company’s improving financials and overall performance when considering an investment in ATRION CORPORATION.
